Inicio>>Signaling Pathways>> Neuroscience>> Dopamine Receptor>>Pericyazine

Pericyazine (Synonyms: Propericiazine, RP 8909, SKF 20,716)

Catalog No.GC38231

La periciazina (Propericiazina) es un agente antipsicÓtico de primera generaciÓn que se utiliza como complemento del tratamiento a corto plazo de estados de ansiedad graves y psicosis.

Products are for research use only. Not for human use. We do not sell to patients.

Pericyazine Chemical Structure

Cas No.: 2622-26-6

Tamaño Precio Disponibilidad Cantidad
1mg
52,00 $
Disponible
5mg
102,00 $
Disponible
10mg
173,00 $
Disponible
25mg
347,00 $
Disponible
50mg
581,00 $
Disponible
100mg
979,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Pericyazine (Propericiazine) is a first-generation antipsychotic drug that is used as an adjunct to the short-term management of severe anxiety states and psychosis[1]. Pericyazine (Propericiazine) is a selective D2-dopamine receptor antagonist[2][3].

[1]. Morley KC, et al. Pericyazine in the treatment of cannabis dependence in general practice: a naturalistic pilot trial. Subst Abuse Rehabil. 2012 May 28;3:43-7. [2]. Farde L, et al. D1- and D2-dopamine receptor occupancy during treatment with conventional and atypicalneuroleptics. Psychopharmacology (Berl). 1989;99 Suppl:S28-31. [3]. Divac N, et al. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370.

Reseñas

Review for Pericyazine

Average Rating: 5 ★★★★★ (Based on Reviews and 16 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pericyazine

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.